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Poly-N-acetylglucosamine (PNAG) is a surface polysaccharide pro-
duced by Staphylococcus aureus and Staphyloccus epidermidis and
is an effective target for opsonic and protective Ab for these two
organisms. Recently, it has been found that Escherichia coli pro-
duces an exo-polysaccharide, designated polyglucosamine, that is
biochemically indistinguishable from PNAG. We analyzed 30 E. coli
strains isolated from urinary tract and neonatal bloodstream in-
fections for the pga locus, PNAG antigen production, and suscep-
tibility to opsonic killing and protection from lethal infection by Ab
to PNAG. Twenty-six of 30 strains carried the pga locus, 25 of 30
expressed immunologically detectable PNAG, and 21 of 30 could be
killed by rabbit IgG specific for the deacetylated form of the
staphylococcal PNAG. Ab to staphylococcal PNAG protected mice
against lethality from five different E. coli strains expressing PNAG.
PNAG expression by both Gram-negative and Gram-positive or-
ganisms could make this antigen a conserved vaccine target for
multiple pathogenic species of bacteria.
vaccine  polyglucosamine  pga locus  ica locus  biofilms
S taphylococcus aureus and coagulase negative staphylococciare the most frequent causes of nosocomial bloodstream
infections (1). One virulence factor in many such infections is the
ability to form a biofilm on synthetic materials (2–4). Most
biofilm-forming strains of S. aureus secrete a large exo-
polysaccharide, poly-N-acetylglucosamine (PNAG) that is in-
volved in intercellular adhesion and is sometimes referred to as
polysaccharide intercellular adhesin or PIA (5–7). PNAG also
protects planktonic cells of S. aureus and Staphylococcus epider-
midis from Ab-independent phagocytic killing by the host im-
mune system (8–10). PNAG is synthesized by proteins encoded
by the icaADBC genes of the intercellular adhesin locus (ica) (6,
11, 12). PNAG is also a promising vaccine candidate for staph-
ylococcal infections (5, 13–17).
Wang et al. (18) recently found that Escherichia coli has a
genetic locus homologous to the staphylococcal ica locus, which
they termed pgaABCD, although it was originally designated as
the ycdSRQP locus in the annotated E. coli K12 genome.
pgaABCD encodes proteins able to synthesize an exo-
polysaccharide that they designated polyglucosamine (PGA),
which they found to be chemically nearly identical to PNAG (18).
They also reported that homologues of the Gram-negative
bacterial pga locus have been identified in a number of other
important pathogens, including Yersinia pestis, Yersinia pseudo-
tuberculosis, Yersinia enterocolitica, Bordetella pertussis, Borde-
tella parapertussis, and Bordetella bronchiseptica (18), but they did
not demonstrate PNAG production by these species. However,
Kaplan et al. (19) showed that Actinobacillus actinomycetem-
comitans and Actinobacillus pleuropneumoniae have a pga-
homologous locus and synthesize PNAG, as do Bordetella spp.
(20). Thus, there is increasing evidence that PNAG can be
synthesized as a surface polysaccharide by a variety of patho-
genic bacteria.
In this work, we analyzed whether 30 clinical isolates of E. coli
from urinary tract and neonatal blood stream infections con-
tained the pga locus, expressed an antigen reactive with anti-
bodies raised to staphylococcal PNAG, could be killed in an
opsonophagocytosis assay with the antibodies to the staphylo-
coccal PNAG and whether mice could be protected by passively
administering Ab to PNAG when challenged with lethal doses of
E. coli by i.p. injection.
Results
Presence of pga Locus and Production of PNAG by E. coli Clinical
Strains. Table 1 summarizes the characteristics of the 30 E. coli
clinical isolates, comprising 18 urinary tract infection (UTI)
isolates and 12 isolates from neonatal bacteremia for the pres-
ence of the pgaA and pgaC loci, which are not always present in
the same operon in Gram-negative bacteria (18). We detected
both of these pga-associated genes in 26 of the 30 clinical E. coli
isolates. None had only one of the genes.
Fig. 1 Left shows the specificity of the PNAG immunoblot
reagents when tested against S. aureus and S. epidermidis strains
known to produce PNAG or deleted for the staphylococcal ica
genes (ica), as well as the sequenced E. coliUTI strain CFT073,
known to have a pga locus (18, 21). We also found that the
clinical E. coli UTI isolate UTI-J expressed detectable PNAG,
whereas UTI-Jpga did not; the UTI-Jpga strain comple-
mented in trans with pPGA reacquired the ability to produce
PNAG. Identical results were obtained with the E. coli BW25113
parental, pga, and transcomplemented strains (data not
shown).
When EDTA extracts prepared from 18 E. coli UTI isolates
and 12 E. coli isolates from neonatal bacteremia were probed for
expression of PNAG, 25 of 30 (83%) produced detectable levels
of PNAG (Fig. 1 Center and Right). All 7 of the E. coli isolates
from neonates known to produce the K1 capsular polysaccharide
also produced PNAG (Fig. 1 Right, lanes H–K, rows 1 and 3). A
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summary of the semiquantitative detection of PNAG production
determined by immunoblot is given in Table 1. The 5 strains
producing no detectable PNAG included the 4 strains negative
for the pga locus. Lack of detectable PNAG in the other strain
could be due to low-level synthesis of PNAG or mutations in the
pga locus preventing production of functional biosynthetic genes.
Opsonic Activity of Ab Raised to S. aureus PNAG Glycoforms Against
Clinical Isolates of E. coli. Fig. 2 presents the opsonic killing activity
against 4 different E. coli clinical isolates using dilutions of rabbit
polyclonal antibodies raised to either a poorly acetylated glycoform
of PNAG designated dPNAG (deacetylated PNAG) or raised to
highly acetylated (95% substitution) native PNAG. Prior results
with Staphylococcus showed that antibodies raised to dPNAG had
superior opsonic killing activity and protective efficacy in animals
(14). Although many E. coli strains can be killed in a bactericidal
assay using only Ab to capsular polysaccharides and complement,
we found that after absorption of the complement source with E.
coli cells to remove any antibody from this reagent, theAb toPNAG
could notmediate bacterial killing in the absence of phagocytes. For
all 4 of the strains at essentially all of the serum dilutions tested,
dPNAG Ab mediated superior opsonic killing compared with Ab
raised to native PNAG. Thus, as we found for S. aureus (14), Ab
raised to the dPNAGantigenmediated better killing thanAb raised
to then native PNAG antigen. Superior opsonic killing activity
correlates with a better ability to deposit opsonically active frag-
ments of the third component of complement on the bacterial
surface (22).
When we evaluated the opsonic killing of the 30 E. coli clinical
isolates by the rabbit polyclonal Ab raised to dPNAG, we found
that 9 of the pga-positive strains were poorly killed in vitro
(10%), 5 (all UTI isolates) were modestly killed (11–30%) and
16 were killed fairly well (30%) (Fig. 3). Results are also
summarized in Table 1. None of theE. coli strains lacking the pga
locus was killed 10%. Several of the strains (indicated on the
graph in Fig. 3) were then used in protection studies.
The specificity for the PNAG antigen of the opsonically active
Ab in antisera raised to dPNAG conjugated to diphtheria toxin
(dPNAG-DT) was shown by the loss of killing activity in the
immune sera, initially diluted to have 40–70% killing activity,
after adsorption withE. coli J.When the sera were adsorbed with
the pga strain, no diminution in opsonic killing was observed
[supporting information (SI) Fig. 4].
Protection Studies. To determine the specificity of the goat
antisera used in the protection studies, we first evaluated binding
of pre- and postimmunization antisera to E. coli J and E. coli
Jpga whole cells by ELISA. Although there was binding of both
the preimmune and immune goat antisera to both strains, there
was no difference in binding of pre or postimmune sera when
using the E. coli Jpga strain (SI Fig. 5), whereas the PGA-
positive E. coli J strain bound the immune serum noticeably
better. Thus, if the preexisting Ab could protect against E. coli
infection, it should be manifest in mice given preimmune serum.
Table 2 summarizes the protective activity in a murine i.p.
infection model of these goat antisera against a selection of E.
Table 1. Molecular and immunological characterization of all E. coli clinical isolate strains
(n  30)
Group
No. of
strains
DNA* PNAG blot† Opsonophagocytic killing‡
     10% 11–30% 31%
UTI 18 2§ 16 3§ 6 9 4 (13%) 5 (17%) 9 (30%)
NICU 12 2§ 10 2§ 2 8 5 (17%) 0 (0%) 7 (23%)
*No. of strains without () or with () pga locus, determined by PCR amplification of pgaA and pgaC genes.
†No. of strains producing PNAG detected by immunoblot: , no signal detected; , weak signal detected; ,
strong signal detected.
‡No. of strains falling into each category; the percentage of all strains (UTI plus NICU groups) is shown in
parentheses.
§All four strains negative for the pga locus were also negative for PNAG by immunoblotting.
Fig. 1. PNAG expression in control strains and E. coli clinical isolates. Cell surface extracts were probed with affinity-purified goat Ab to PNAG. (Left) Control
strains. Lanes: A1, S. aureus MN8; A2, S. aureus MN8ica; A3, S. epidermidis M187; B1, E. coli CTF073; B2, E. coli UTI-J; B3, E. coli UTI-Jpga; B4, E. coli
UTI-JpgapPGA. (Center) Clinical UTI isolates from different patients collected in the U.S. Lanes: C1, UTI-D; C2, UTI-E; C3, UTI-F; C4, UTI-G; D1, UTI-H; D2, UTI-I;
D3, UTI-J; D4, UTI-K; E1, UTI-L; E2, UTI-MI; E3, UTI-N; E4, UTI-O; F1, UTI-P; F2, UTI-Q; F3, UTI-R; F4, UTI-S; G1, UTI-T; G2, UTI-U. (Right) Neonatal isolates from different
patients in Europe and the U.S. Lanes: H1, NICU-1; I1, NICU-2; J1, NICU-3; K1, NICU-4; L1, NICU-5; H2, NICU-6; I2, NICU-7; J2, NICU-8; K2, NICU-9; L2, NICU-10; H3,
NICU-11; I3, NICU-12. Extracts from isolates in the first and last rows (rows 1 and 3) are from E. coli strains also positive for the K1 capsular antigen.
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coli strains. For each E. coli strain, we selected a challenge dose
that would kill at least 75% of the mice. Goat Ab was used
because of requirements for significant volumes of sera in these
experiments, but this serum has been shown to have opsonic
killing activity to S. aureus strains comparable with that of the
rabbit antiserum used in the opsonic assays (Fig. 3) (14). This
conclusion was verified by using 3 strains of E. coli (data not
shown). As can be seen (Table 2), for the 5 E. coli strains
expressing PNAG, there was significant protection ranging from
58% to 88% of animals given dPNAG-specific immune serum,
whereas animals given preimmune goat serum had survival rates
of 0–25% despite the presence of non-PNAG-specific Ab to E.
coli in the preimmune serum. Furthermore, although both the
preimmune and immune antisera bound to the E. coli Jpga
cells, there was no protective efficacy against this strain or
against the E. coli UTI-H strain, which is negative for the pga
locus.
When an antiserum raised to an irrelevant antigen in con-
junction with the same adjuvants as used with the dPNAG-DT
conjugate was given to mice, no protection against either E. coli
J or E. coli Jpga was observed (Table 2). All dead mice had
bacterial dissemination into their spleens, indicative of bactere-
mic spread from the initial focus of infection, whereas survivors
had spleens lacking detectable bacteria as determined after the
mice were killed.
Discussion
E. coli is an important cause of gastrointestinal diseases (23–25),
UTIs (26–28), and neonatal meningitis and sepsis (29, 30), but
the potential for vaccination against these strains has been
deemed low because of the chemical and serologic variability of
the most efficacious target antigens, lipopolysaccharide O anti-
gens and capsular polysaccharides. Finding a conserved surface
polysaccharide among diverse E. coli strains would raise the
potential for use of such an antigen as a vaccine. Furthermore,
finding that such an antigen was also expressed by other common
but phylogenetically diverse pathogens, such as staphylococci,
further raises interest in the vaccine potential of such an antigen.
Given that vaccines injected into humans to prevent Streptococ-
cus pneumoniae invasive disease, as well asNeiserria meningitidis,
Haemophilus influenzae type b, and Salmonella enterica serovar
Typhi infections are all composed of capsular polysaccharides as
the major vaccine component, finding a broadly expressed
surface polysaccharide such as PNAG among diverse pathogens
that is a target for opsonic and protective Ab represents a
potential means to have a vaccine effective against a wide
number of important human bacterial pathogens.
As a first step in determining whether PNAG has such broad
vaccine potential, we followed up on the recent findings of Wang
et al. (18), who showed that strains of E. coli for which a
sequenced genome has been produced all contain a genetic locus
Fig. 2. Opsonophagocytic killing activity of goat Ab raised to either dPNAG
(black diamonds) or PNAG (gray squares) against E. coli strains UTI-J, UTI-P,
UTI-U, and NICU10. Points represent means of triplicates; SE bars are5% and
are contained within each point.
Fig. 3. Opsonophagocytosis of theE. coli clinical isolates. Circles, UTI isolates. Squares, isolates from neonates in the NICU. A symbol indicates mean of triplicates,
error bars the SD. Six isolates used in the protection studies are noted, as is E. coli UTI-Jpga, for which only background levels of killing of were achieved. UTI
strain H lacks the pga locus.
Table 2. Protection studies in an intraperitoneal murine model
Strain
Dose per
mouse, cfu*
Preimmune
goat serum Immune serum
Anti-dPNAG-DT goat
UTI-J 2.5  108 0/8 (0%)† 5/8 (63%)‡
UTI-Jpga§ 1.0  109 2/8 (25%) 2/8 (25%)
UTI-H§ 5.0  108 0/8 (0%) 0/8 (0%)
UTI-P 2.5  108 0/8 (0%) 7/8 (88%)‡
UTI-U 5.0  108 1/8 (13%) 7/8 (88%)‡
NICU-3 3.9  108 0/8 (0%) 7/8 (88%)‡
NICU-10 1.25  108 4/24 (17%) 14/24 (58%)‡
Anti-human IgG
UTI-J 1.0  108 1/8 (13%)† 2/8 (25%)
UTI-Jpga§ 2.0  109 1/8 (13%) 1/8 (13%)
*Minimal bacteria concentration necessary to kill at least 75% of the mice in
each group.
†No. of surviving mice over the total mice used; percentage survival is in
parentheses.
‡Survival58% from immune goat serum significant at P0.01, Fisher’s exact
test compared with normal goat serum giving survival of 25%.
§Lacks pga locus and PNAG production.
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homologous to the staphylococcal icaADBC locus, designated
pgaABCD by them (18). The presence of a pga locus is associated
with the production of PNAG. In both staphylococci and E. coli,
the PNAG polymer promotes biofilm formation and is cell
surface-associated (5, 6, 18). In staphylococci, PNAG has been
found to be a virulence factor (8, 31–33) and target for protective
Ab (14–16). In this work, we report that a high percentage of E.
coli UTI and neonatal bacteremia isolates contain the ica-
homologous pga genetic locus and synthesize PNAG that is
immunologically cross-reactive with PNAG isolated from S.
aureus, and the production of PNAG byE. coli allows opsonically
active antibodies raised to the S. aureus dPNAG antigen to
mediate in vitro killing of these organisms. When the pga locus
was deleted from E. coli strains BW25113 and clinical UTI
isolate strain J, they no longer synthesized PNAG, but when the
pga locus was added back in trans, PNAG synthesis was restored.
In addition, clinical isolates lacking detectable pgaABCD also
failed to produce PNAG. One isolate contained the pgaA and
pgaC genes but nonetheless failed to produce detectable PNAG,
potentially as a result of a mutation or gene repression. Overall,
production of immunologically cross-reactive PNAG antigen was
detected in 83% of 30 clinical isolates of E. coli.
To explore the potential of PNAG to vaccinate against E. coli
infections, we initially compared the opsonic killing activity of
antibodies raised with a mostly deacetylated form of PNAG (dP-
NAG, 15% residual N-acetyl groups) with that of antibodies
raised to native PNAG (95% N-acetyl groups). Prior results with
staphylococci have shown that the Ab to the dPNAG antigen has
greater activity in opsonizing S. aureus and S. epidermidis for
phagocytic killing (14, 22, 34) and in mediating protective efficacy
in experimental animal infections (14, 34). Ab to dPNAG did not
mediate killing of E. coli in the absence of phagocytes. As we found
with staphylococci, Ab raised to the dPNAG had superior opsonic
activity againstE. coli. Themolecular basis for this phenomenonhas
been elucidated by the studies of Vuong et al. (10) by using S.
epidermidis, wherein partial deacetylation of PNAG by the IcaB
protein is needed to retain the antigen on the bacterial cell surface.
We have found that the IcaB protein in S. aureus behaves identically
(N.C., K.K.J., T.M.-L., D. B. Pier, C. Kelly-Quintos, D.A.G., J.
Azeredo, and G.B.P, unpublished observations). Therefore, the
epitopes recognized by the antibodies raised to dPNAGare present
at a higher density on the bacterial cell surface, which is needed for
efficient opsonic killing.
We next analyzed the protective efficacy of Ab raised to
dPNAG conjugated to DT (14) against several E. coli strains
expressing high or moderate levels of PNAG, as well as some
negative controls comprising E. coli strains lacking the pga locus.
Compared with normal goat serum, the goat serum raised to
dPNAG-DT effectively protected against lethal sepsis after i.p.
infection, except with the pga-negative controls, as expected.
Although the i.p. infection model might be considered to mimic
aspects of E. coli peritonitis, including bacteremic spread as
evidenced by the presence of bacteria in the spleens of nonpro-
tected animals, it clearly does not mimic the various manifesta-
tions of E. coli UTI or neonatal bacteremia. Nonetheless, a
high-dose challenge model is a robust initial test of a vaccine’s
potential efficacy, primarily evaluating the in vivo activities of the
antibodies and expression of the antigen. Although additional
studies are needed to determine whether Ab to dPNAG can
protect against experimental E. coli bladder infections (35, 36)
or bacteremia emanating from the gastrointestinal tract (37, 38),
these initial studies validate the potential of dPNAG as a
protective vaccine for diverse and common pathogens such as E.
coli, S. aureus, and coagulase-negative staphylococci. In addi-
tion, if pathogens such as Bordetella spp., Yersinia spp., A.
actinomycetemcomitans, and others known to have a pga-
homologous genetic locus (18, 19) also produce PNAG in a
manner and form rendering antibodies to the antigen opsonic
and protective, then a properly constructed PNAG-based vac-
cine could be protective against a broad array of human and
animal pathogens. Currently, no such broadly expressed, pro-
tective surface polysaccharide antigen, the basis for most suc-
cessful vaccines used in humans to elicit antibodies that kill
bacterial pathogens, has been identified.
Materials and Methods
Strains and Media. To evaluate the expression of PNAG, we used
several strains of staphylococci, including PNAG-positive S.
aureus MN8 (15) and S. epidermidis M187 (39) and PNAG-
negative S. aureus MN8ica (8). E. coli strains used included
CFT073, a urinary tract isolate previously shown to contain the
pga locus (18), and 30 clinical isolates of E. coli collected over
different periods of time and also geographically distant. These
isolates included 18 obtained from 18 different patients hospi-
talized at Brigham and Women’s Hospital, Boston, MA, and
were provided by the Clinical Microbiology Laboratory, cour-
tesy of Andrew Onderdonk, and 12 blood isolates from patients
in neonatal intensive care units (NICU) in Europe and the U.S.
which were kindly provided by Kwang-Sik Kim, Baltimore, MD,
or Peter W. Taylor, London, U.K. Seven of the E. coli isolates
from neonates were known to express the K1 capsular polysac-
charide frequently found among isolates from such patients (40).
S. epidermidis, S. aureus, and E. coli strains were grown for 16 h
at 37°C in tryptic soy broth/1% (gram percent) glucose (TSBG).
Construction of E. coli pga-Deleted and Complemented Strains. The
pga locus was replaced with a chloramphenicol acetyltransferase
cassette by the PCR-mediated one-step method of gene inacti-
vation described by Datsenko and Wanner (41). To accomplish
this goal, E. coli BW25113 and the clinical UTI isolate strain J
were first transformed with the red recombinase expression
plasmid pKD46 then grown overnight at 25°C in SOC medium
(2 102 g/ml Bacto-tryptone/5 103 g/ml yeast extract/5.84
104 g/ml NaCl/1.86 104 g/ml KCl/20 mMMgCl2/20 mMGlc,
pH 7.0) containing 100 g of ampicillin per ml and 10 mM
L-arabinose. The next day, the cells were collected by centrifu-
gation, washed three times with deionized H2O containing 10%
glycerol, and resuspended at a 50-fold concentration over the
original volume. A PCR product of the chloramphenicol acetyl-
transferase cassette was generated from plasmid pKD3 by using
the primer pair pgadeleteFWD (5-CCGGACTAGCGCTTTT-
TCTGAAACCACCATTTTTATTTGCCCCTGGCTGG-
GTGTAGGCTGGAGCTGCTTC-3) and pgadeleteREV
(5-AAGTAGCAGAAAAAGGTGCCCGAAAACCAAAT-
GGGCTTTGAAACTTCTTACATATGAATATCCTCC-
TTAG-3). The PCR product had 5 and 3 ends homologous to
the 5 and 3 ends of the E. coli pga locus and was gel-purified
by using the QIAquick gel extraction kit (Qiagen, Valencia, CA).
Electrocompetent E. coli cells were transformed with the puri-
fied PCR product by electroporation, and transformants were
selected on LB agar containing 30g of chloramphenicol per ml.
Chloramphenicol-resistant bacteria were analyzed by PCR to
ascertain that the chromosomal pga locus was deleted (pga
strains) and were then cured of the pKD46 plasmid by two
rounds of growth at 42°C in the absence of ampicillin. The E. coli
BW25113 parental and pga strains were used to confirm the
specificity of the immunoblot, and the pga strain was used to
absorb antisera used in the opsonic killing assay.
To transcomplement the pga-deletion mutants, the entire pga
locus was amplified from E. coli BW25311 DNA by PCR using
primers pgaexpressFWD (5-ATGTATTCAAGTAGCA-
GAAAAAGGTGC-3) and pgaexpressREV (5-GTGTT-
TACGCCCGGACTAGC-3) and cloned into the arabinose-
inducible pBAD-TOPO vector (Invitrogen, Carlsbad, CA). The
DNA sequence of the insert in the resulting construct, pPGA,
was determined to confirm identity to the known pga DNA
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sequence and then used to transform the pga-deletion mutant
strains by electroporation. Transformants were selected on LB
agar containing 100 g ampicillin per ml. Addition of arabinose
to the growthmediumwas not necessary for sufficient expression
levels in pPGA-complemented strains.
Detection of PNAG Production by Bacteria. Immunoblots for pro-
duction of PNAG were performed essentially as described previ-
ously (7, 42) with minor modifications. Bacteria were grown to
stationary phase in TSBG, and the cultures were diluted in this
growth medium to produce an A600 	 1.5. Bacterial cells were
pelleted by centrifugation, and equivalent amounts of each of the
different bacterial preparations were resuspended in 300 l of 0.5
M EDTA (pH 8.0) and incubated for 5 min at 100°C. Cells were
removed by centrifugation at 10,500 g for 6min, and 100l of the
supernatant was then incubated with 10 l of proteinase K (20
mg/ml; Qiagen) for 60 min at 60°C. Proteinase K was heat-
inactivated by incubating for 30 min at 80°C. This solution was
diluted 3-fold in Tris-buffered saline (20 mM TrisHCl/150 mM
NaCl, pH 7.4), except for the extract from S. epidermidis M187,
which was diluted 1,000-fold because of hyperproduction of PNAG
by this strain, and 200 l of each dilution was immobilized on a
nitrocellulose filter attached to a slot-blot vacuum manifold. The
filter was blocked with a solution of 1%BSA, then incubated for 2 h
with a rabbit Ab raised to S. aureus PNAG conjugated to DT,
produced as described previously (14) and further purified on an
affinity column, also as described previously (22). The secondary
Ab used was a horseradish peroxidase-conjugated anti-rabbit IgG
Ab (Southern Biotech, Birmingham, AL) diluted 1:6,000, and
detection of the PNAG antigen used the enhanced chemilumines-
cence (Amersham, Piscataway, NJ) Western blotting system.
Detection of the pga Locus in E. coli Clinical Isolates by PCR.Genomic
DNA fromE. coli strains was extracted by using a DNeasy tissue kit
(Qiagen). Primers used for the detection of the pgaA (5-
GGCTTTGAAACTTCTTACTGC-3 and 5-CCTGTTTATCT-
TGCCCGGCC-3) and pgaC (5-ATGATTAATCGCATCG-
TATCG-3 and 5-CATCGGTTCCACAATATATGC-3) were
custom synthesized by Qiagen Operon (Alameda, CA). For the
PCR we added 25 l of PCR supermix high-fidelity (Invitrogen),
0.5 l of each primer, and 2 l of DNA from the bacterial strains.
PCR conditions comprised an initial 5-min denaturation step at
94°C followed by 32 cycles of 30 s at 94°C, 30 s at 50°C, and 45 s at
72°C, and a final extension step of 5 min at 72°C.
Antisera. We used antibodies raised to either native S. aureus
PNAG, wherein the glucosamine monosaccharides contained
95% acetate groups, or dPNAG, wherein the level of substitution
with acetate groups was 15% (29). Both polysaccharides were
conjugated to DT as described (14) and used to raise antibodies in
rabbits, also as described previously (14). The dPNAG-DT conju-
gate was also used to immunize a goat as described previously (20).
Specificity of the rabbit antiserum used in the opsonophagocytic
assay was evaluated by adsorbing the sera with either PNAG-
expressing E. coli J or the isogenic PNAG-negative E. coli pga
strain. Specificity of the goat antisera for PNAG expression by E.
coliwas evaluated bywhole-cell ELISAusing theE. coli J and Jpga
strains. For some control experiments, we used a goat antiserum to
human IgG raised by using the same adjuvants and immunization
schedule aswas used for the dPNAG-DTconjugate vaccine andwas
supplied by Lampire Biological Laboratories, Pipersville, PA. We
have shown previously that the goat antiserum has comparable
binding and opsonic activity against PNAG-producing S. aureus as
does the rabbit antiserum raised to the dPNAG-DT conjugate (14).
Opsonic Killing of E. coli Clinical Isolates. WBC were prepared from
fresh human blood collected from healthy adult volunteers. Twen-
ty-five milliliters was mixed with an equal volume of dextran/
heparin buffer and incubated at 37°C for 1 h. The upper layer
containing the leukocytes was collected, the cells were pelleted by
centrifugation, and the remaining erythrocytes were removed by
hypotonic lysis after resuspension of the cell pellet in 1% NH4Cl
with incubation for 10 min at room temperature. WBC were then
washed three times and resuspended with RPMI containing 15%
heat-inactivated (56°C, 30 min) FBS (RPMI/FBS). Trypan blue
staining was used to determine the number of viable leukocytes,
then the final WBC count was adjusted to 2.5  107 WBC per ml.
The complement source (1 ml of baby rabbit serum diluted 1:10 in
RPMI/FBS) was adsorbed twice at 4°C for 45 min with continual
mixing using bacteria resuspended from a pellet containing 109
cfu of E. coli BW25113 to remove natural Ab that mediated
bactericidal killing of some of the target E. coli strains. The rabbit
antisera were diluted 1:10 in RPMI/FBS and absorbed twice at 4°C
for 45 min with continual mixing using bacteria resuspended from
a pellet containing 109 cfu of E. coli BW25113pga. After
absorption, the complement solution and the Ab were centrifuged
and filter-sterilized. The bacterial strains to be evaluated for phago-
cyte-dependent killing activity of the rabbit Ab to PNAG were
grown overnight in TSBG and then adjusted to an A650 	 0.4. A
1:100 dilution (3–6 107 cfu/ml) was then made in RPMI/FBS for
use in the killing assay.
The opsonophagocytic assay was performed with 100 l of
leukocytes/100 l of bacteria/100 l of the complement solution/
100 l of a 1:10 or higher dilution of the Ab. Several controls were
used: each component individually and all of the possible combi-
nations of the individual components with onemissing. Themissing
volume was made up with 100 l of RPMI/FBS. The reaction
mixture was incubated on a rotor rack at 37°C for 90min. The tubes
were vortexed for 15 s, and then dilutions were made in TSB with
0.025% Tween (to prevent bacterial sticking to pipette tips and the
walls of dilution vessels); samples were than plated onto tryptic soy
agar plates. The percentage of killing was calculated by determining
the ratio of the cfu surviving in the tubes with bacteria, leukocytes,
complement and Ab, to the cfu surviving in the tubes with bacteria,
complement, leukocytes, and RPMI/FBS. Each assay was done in
triplicate and repeated two or three times.
Murine Lethality Model. To evaluate the in vivo protective efficacy
of Ab to PNAG, we used an i.p. infection model in mice, as
described previously (8, 14). Briefly, groups of eight mice (FVB,
female, 6–8 weeks of age) were immunized i.p. 24 h before and 4 h
after infection with 0.3 ml of normal goat serum or immune goat
serum raised against staphylococcal dPNAG conjugated to DT.
Somemice received a heterologous immune serum raised to human
IgG with the same adjuvants and schedule as used with the
dPNAG-DT conjugate. Bacteria were grown overnight in TSBG
and then resuspended in sterile PBS to5 108 to 5 109 cfu/ml,
depending on the strain. For each strain, we selected aminimal dose
that would kill at least 75% of the mice. Mice were challenged i.p.
with a dose of 1.25  108 to 1  109 cfu in 0.2 ml of PBS and
monitored at least twice daily. When mice became moribund, as
defined by hunched appearance, markedly increased respiration
rate, piloerection, and lack of an ability tomove in response to being
touched, they were considered moribund; they were killed and
counted as dead for these experimental outcomes. After death, the
spleens of the mice were removed, homogenized in RPMI, and
cultured on tryptic soy agar andMacConkey agar to determine that
the E. coli had disseminated from the initial site of infection.
Statistical Analysis. Differences in outcomes in the protection
studies were determined by Fisher’s exact test.
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